结膜下地塞米松植入治疗周围性溃疡性角膜炎

Q3 Medicine

American Journal of Ophthalmology Case Reports Pub Date : 2025-07-09 DOI:10.1016/j.ajoc.2025.102379

Hashem H. Ghoraba, Chris Or, Aneesha Ahluwalia, Bethlehem Mekonnen, Cigdem Yasar, Negin Yavari, Quan Dong Nguyen

{"title":"结膜下地塞米松植入治疗周围性溃疡性角膜炎","authors":"Hashem H. Ghoraba, Chris Or, Aneesha Ahluwalia, Bethlehem Mekonnen, Cigdem Yasar, Negin Yavari, Quan Dong Nguyen","doi":"10.1016/j.ajoc.2025.102379","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To report a case of peripheral ulcerative keratitis (PUK) successfully treated with subconjunctival dexamethasone implant (Ozurdex®) injection.</div></div><div><h3>Observations</h3><div>An 82-year-old female presented with PUK in the right eye. Systemic immunosuppressive treatment with steroids and methotrexate resulted in complete healing. The patient developed adverse events that led to discontinuation of systemic therapy. Nine months after presentation, the PUK recurred, and the patient declined to restart systemic therapy. Subconjunctival dexamethasone implant injection resulted in complete resolution. The patient received three injections over a period of 10 months. No scleral melt or ocular hypertension was noted 11 months after the first injection.</div></div><div><h3>Conclusions and importance</h3><div>Subconjunctival dexamethasone implant injection can be a well-tolerated treatment option for peripheral ulcerative keratitis.</div></div>","PeriodicalId":7569,"journal":{"name":"American Journal of Ophthalmology Case Reports","volume":"39 ","pages":"Article 102379"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Subconjunctival dexamethasone implant (Ozurdex) for peripheral ulcerative keratitis\",\"authors\":\"Hashem H. Ghoraba, Chris Or, Aneesha Ahluwalia, Bethlehem Mekonnen, Cigdem Yasar, Negin Yavari, Quan Dong Nguyen\",\"doi\":\"10.1016/j.ajoc.2025.102379\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>To report a case of peripheral ulcerative keratitis (PUK) successfully treated with subconjunctival dexamethasone implant (Ozurdex®) injection.</div></div><div><h3>Observations</h3><div>An 82-year-old female presented with PUK in the right eye. Systemic immunosuppressive treatment with steroids and methotrexate resulted in complete healing. The patient developed adverse events that led to discontinuation of systemic therapy. Nine months after presentation, the PUK recurred, and the patient declined to restart systemic therapy. Subconjunctival dexamethasone implant injection resulted in complete resolution. The patient received three injections over a period of 10 months. No scleral melt or ocular hypertension was noted 11 months after the first injection.</div></div><div><h3>Conclusions and importance</h3><div>Subconjunctival dexamethasone implant injection can be a well-tolerated treatment option for peripheral ulcerative keratitis.</div></div>\",\"PeriodicalId\":7569,\"journal\":{\"name\":\"American Journal of Ophthalmology Case Reports\",\"volume\":\"39 \",\"pages\":\"Article 102379\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Ophthalmology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S245199362500132X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S245199362500132X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的报告1例结膜下地塞米松植入物（Ozurdex®）治疗外周性溃疡性角膜炎（PUK）的临床疗效。患者为82岁女性，右眼出现PUK。全身免疫抑制治疗类固醇和甲氨蝶呤导致完全愈合。患者出现不良事件，导致停止全身治疗。9个月后，PUK复发，患者拒绝重新开始全身治疗。结膜下地塞米松种植体注射导致完全溶解。病人在10个月内接受了三次注射。第一次注射后11个月未见巩膜融化或高眼压。结论及重要性结膜下地塞米松种植体注射治疗周围性溃疡性角膜炎是一种耐受性良好的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Subconjunctival dexamethasone implant (Ozurdex) for peripheral ulcerative keratitis

Purpose

To report a case of peripheral ulcerative keratitis (PUK) successfully treated with subconjunctival dexamethasone implant (Ozurdex®) injection.

Observations

An 82-year-old female presented with PUK in the right eye. Systemic immunosuppressive treatment with steroids and methotrexate resulted in complete healing. The patient developed adverse events that led to discontinuation of systemic therapy. Nine months after presentation, the PUK recurred, and the patient declined to restart systemic therapy. Subconjunctival dexamethasone implant injection resulted in complete resolution. The patient received three injections over a period of 10 months. No scleral melt or ocular hypertension was noted 11 months after the first injection.

Conclusions and importance

Subconjunctival dexamethasone implant injection can be a well-tolerated treatment option for peripheral ulcerative keratitis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Ophthalmology Case Reports Medicine-Ophthalmology

CiteScore

2.40

自引率

0.00%

发文量

513

审稿时长

16 weeks

期刊介绍： The American Journal of Ophthalmology Case Reports is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished case report manuscripts directed to ophthalmologists and visual science specialists. The cases shall be challenging and stimulating but shall also be presented in an educational format to engage the readers as if they are working alongside with the caring clinician scientists to manage the patients. Submissions shall be clear, concise, and well-documented reports. Brief reports and case series submissions on specific themes are also very welcome.